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Background: Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2).
This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic
breast cancer who had received prior chemotherapy for their metastatic disease.
Methods: This multicenter, open-label, single arm study enrolled patients with non-triple-negative breast cancer,
pretreated with anthracycline, taxanes and capecitabine, and who failed in the metastatic setting at least 1 and at most
4 prior chemotherapy regimens and at least one endocrine drug for hormone receptor-positive patients as well as at
least one anti-Her2 drug for Her2-positive patients. The primary end point of this study was progression free survival
(PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and
toxicity. Apatinib was administered as 500 mg daily on days 1 through 28 of each 4-week cycle.
Results: 38 patients were enrolled with a median age of 49 years (range, 35 to 62 years) and received apatinib for a
median of 4 cycles (range from 0 to 10 cycles). 18 (47.4%) patients experienced dose reduction during treatment. The
median relative dose intensity (relative to assigned dose for each cycle) was 82% (range, 45.0% to 100.0%). Median
follow-up time was 10.1 months. Median PFS of all 38 patients was 4.0 months (95% confidence interval (CI), 2.8
m – 5.2 m). 36 patients were eligible for efficacy analysis. ORR was 16.7% (6/36). DCR was 66.7% (24/36). Median OS was
10.3 months (95% CI, 9.1 m – 11.6 m). The most common grade 3/4 treatment-related AEs were hypertension (20.5%),
hand-foot syndrome (10.3%), and proteinuria (5.1%). Of three possibly drug-related SAEs recorded in the study, 2 (3.4%)
deaths occurred within 28 days of last treatment and were both considered to be the result of disease progression.
The other one was grade 2 diarrhea needing hospitalization.
Conclusions: Apatinib exhibited objective efficacy in heavily pretreated, metastatic non-triple-negative breast cancer with
manageable toxicity, and it might be better to be tested in breast cancer with high angiogenesis dependency.
Trial registration: ClinicalTrials.gov: NCT01653561.
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Breast cancer is the most common malignancy in women
in the world wide [1]. Although effective chemotherapy
and hormonal therapy for early breast cancer have reduced
5-year recurrence rates and 15-year mortality rates [2],
many patients still experience disease relapse or metastasis.* Correspondence: huxicun@gmail.com
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reproduction in any medium, provided the orFor patients with metastatic non-triple-negative breast
cancer, endocrine therapy or HER2-targeted therapy plays
an important role in the treatment besides chemotherapy,
however nearly all patients will eventually develop drug
resistance. Novel drugs for such patients with MBC are
therefore needed.
Vascular endothelial growth factor (VEGF) and its
receptors (VEGFRs) play a critical role in angiogenesis
of breast and other cancers [3]. VEGFRs are receptor
tyrosine kinases, including VEGFR-1, VEGFR-2, and
VEGFR-3. VEGFR-2 is now thought to be the major
mediator of the mitogenic and angiogenic effects ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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body designed to block VEGF-A and has showed efficacy
in MBC [5-8] and other several cancers [9-12]. VEGFR
inhibitors, including sorafenib and sunitinib, have been
investigated in the treatment of MBC. They are both
orally administered small-molecular inhibitors of multiple
tyrosine kinases (TKI), involved in tumor progression and
angiogenesis including VEGFR-1 (Flt1), VEGFR-2 (KDR),
and VEGFR-3 (Flt4), platelet-derived growth factor recep-
tors (PDGFRs), and c-KIT [13,14]. However, single agent
of sorafenib did not exhibit activity when measured by
tumor shrinkage in patients with MBC who had received
prior standard chemotherapy [15,16]. Sunitinib has some
antitumor activity, but relatively high toxicity and no add-
itional benefit when combined with chemotherapy [17].
Apatinib is also an orally administered small-molecular
receptor TKI with potential antiangiogenic and antineo-
plastic activities. It selectively binds to and inhibits VEGFR-
2, which may inhibit VEGF-stimulated endothelial cell mi-
gration and proliferation and decrease tumor microvessel
density [18].
The investigators' phase I and phase II studies showed
that apatinib has encouraging antitumor activity and man-
ageable toxicities [18-20]. The aim of this study is to assess
efficacy and safety of apatinib in heavy-pretreated patients
with non-triple-negative metastatic breast cancer.
Methods
Patients
Inclusion criteria included women (≥18 and ≤70 years of
age) with a histologically confirmed MBC diagnosis. All
patients should have at least one extracranial measurable
site of disease according to Response Evaluation Criteria
in Solid Tumors (RECIST) 1.0 criteria that has not been
previously irradiated and experienced at least 1 and at
most 4 regimens, and failed from the last chemotherapy
regimen. Pretreated anthracycline, taxanes and capecita-
bine (any rational reason for no use of capecitabine is ac-
ceptable) are mandatory. Women diagnosed with human
epidermal growth factor receptor positive (HER2+) should
have failed for at least 1 anti-HER2 therapy (any rational
reason for no use of anti-HER2 therapy is acceptable).
HER2+ is defined as +++ staining on immunohistochemis-
try or FISH/CISH positive for gene amplification. Women
diagnosed with Hormonal receptor (HR) + should have
failed for at least 1 hormonal therapy or experienced re-
lapse during treatment or within 6 months of the last dose
of hormonal therapy. In addition, patients were required to
have Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 or 1, and to have completed all prior
chemotherapy, radiotherapy, target therapy and operation
at least 4 weeks before study entry. All patients had ad-
equate hematologic, coagulation, hepatic, renal, and cardiac
function, and had provided written, informed consent.Patients were excluded if they were triple-negative breast
cancer, had a known history of brain metastasis, arterial/
venous embolic events, uncontrolled hypertension with
mono-drug therapy, ischemia of the myocardium (≥ grade 2)
or myocardial infarction, arrhythmia (≥ grade 2, QTcF
> 470 ms) or New York Heart Association Class III/IV,
gastrointestinal disorder or other factors that could interfere
with drug absorption, were on anti-coagulation therapy,
had prior treatment with a VEGFR, PDGFR or s-SRC TKI
(Bevacizumab is permitted). Patients whose urine pro-
tein ≥++ and confirmed >1.0 g by the 24 h quantity or
cumulative doses of doxorubicin and epirubicin before
inclusion have surpassed 300 mg/m2 and 600 mg/m2,
respectively, were also excluded. The Fudan University
Shanghai Cancer Center Ethic Committee for Clinical
Investigation approved the study.
Drug administration
A starting dose of apatinib was administered 500 mg daily
on days 1 through 28 of each 4-week cycle. Apatinib was
provided by the sponsor, Jiangsu HengRui Medicine Co.,
Ltd. Two dose reductions will be allowed to 375 and then
250 mg/d if patients experienced grade 4 hematologic
adverse events or grade 3 hypertension, hand and foot
syndrome, proteinuria or other grade 3/4 nonhematologic
adverse events which investigators considered dose reduc-
tion necessary. Apatinib was administered until consent
withdrawal, disease progression, unacceptable toxicity after
two dose of reductions, or toxicity requiring cumulative
dose interruption of more than 14 days or twice in an initi-
ating treatment cycle happened.
Study design and assessments
This was an open-label, single-arm, phase II study
(ClinicalTrials.gov NCT01653561) conducted at six centers
in China. The primary end point of this study was progres-
sion free survival (PFS). Secondary end points included ob-
jective response rate (ORR), disease control rate (DCR),
overall survival (OS), and toxicity. PFS was defined to be
the time from registration to the date of disease progres-
sion or death resulting from any cause. OS was defined to
be the time from registration to the date of death resulting
from any cause or the last follow-up visit. Follow-up every
2 months was done until death or lost were met.
Patients eligible were evaluated by spiral CT or MRI
scan at baseline and every 2 cycles (8 weeks) thereafter
until disease progressed. ORR was defined as the propor-
tion of eligible patients who achieved a confirmed CR or
PR by RECIST 1.0 criteria evaluated by the investigators.
DCR was defined as the proportion of patients who
achieved CR, PR and SD for at least 8 weeks.
Adverse events (AEs) were assessed and graded in
accordance with the Common Terminology Criteria for
AEs, version 4.0. The safety evaluation was continued
Table 1 Patient characteristics
Characteristics p value
Median age, range (years) 49(35, 62)
ECOG status, n (%)
0 7(18.4)
1 31(81.6)
ER status, n (%)
Negative 8(21.1)
Positive 30(78.9)
PR status, n (%)
Negative 17(44.7)
Positive 21(55.3)









Prior chemotherapy, n (%)















ECOG, Eastern Cooperative Oncology Group.
ER, estrogen receptor; PR, progesterone receptor.
HER2, human epidermal growth factor receptor 2.
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to grade 1 or 0 from any acute toxicities associated with
apatinib.
Statistical analysis
In sample size estimate, 5 months of accrual period and
3 months of follow-up period were assumed. The study
was designed with two-sided, α = 0.05, 80% power to detect
a null median PFS of 2 months and experimental median
PFS of 4.5 months (n = 50). Assuming a 20% dropout rate,
final accrual number was 60.
Patients who received at least one dose of apatinib
were included in the survival and safety analysis. PFS
and OS were estimated using Kaplan-Meier method.
The Statistical Package for the Social Sciences software
(SPSS) version 16.0 was used for all statistical analyses.
Results
The study was closed early after the accrual of 38 eligible
patients by the sponsor due to the company’s new policy in
September, 2012. The analysis was conducted 6 months after
the last eligible patient was enrolled in December, 2012.
Patients characteristics
A total of 38 patients were enrolled between December,
2011 and September, 2012. Patients’ characteristics at
baseline are listed in Table 1. The most common sites of
metastatic disease were liver, lymph nodes, lung, and
bone. 33 (86.8%) patients presented with at least one site
of visceral metastasis. Of the 9 patients with HER2-positive
tumors, 3 were pretreated with trastuzumab. All patients
had received prior treatment with both an anthracycline and
a taxane. 13 (34.2%) patients were heavily pretreated, having
received three or more prior chemotherapy regimens.
All 38 patients received at least one dose of apatinib and
were included in survival and safety analyses (Figure 1). 36
patients were eligible for response evaluations for one case
of consent withdrawal and one case of dropout. Treat-
ment discontinued in 33 patients at the last follow-up on
December 29, 2012. 26 (78.8%) patients discontinued be-
cause of disease progression, 4 (12.1%) because of adverse
events (drug-related adverse events),1 (2.6%) because of
death, 1 (2.6%) because of dropout, and 1 (2.6%) because
of consent withdrawal. Patients received a median of four
treatment cycles (range, 0 to 10). Dose interruption during
at least one cycle was required in 27 patients (73.7%). 18
(47.4%) patients experienced dose reduction during treat-
ment, of which 13 patients received a dose reduction to
375 mg/d and 5 to 250 mg/d. Nonhemotologic toxicities
were the only reason for dose interruption or reduction.
The median number of days for treatment was 98.5
(range, 9 to 251) days, and the median relative dose inten-
sity (relative to assigned dose for each cycle) was 82%
(range, 45.0% to 100.0%).Efficacy
Median follow-up time was 10.1 months (range, 4.4 to
12.7 months). Median PFS of all 38 patients was 4.0 months
(95% confidence interval (CI), 2.8 m – 5.2 m) (Figure 2). 36
patients were eligible for efficacy analysis. 1 patient got a
confirmed complete response and 5 got partial response
according to RECIST 1.0 criteria. ORR was 16.7% (6/36). 2
cases with PR disease were seen in 9 patients (22.2%) with
Figure 1 Patient enrollment and outcomes (flowchart).
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(50%, 18/36) patients had stable disease for at least 8 weeks
and 3 (8.3%, 3/36) patients had no disease progression at
24 weeks. DCR was 66.7% (24/36). 19 patients were still alive
at the time of analysis. Median OS was 10.3 months
(95% CI, 9.1 m – 11.6 m) (Figure 3).
Safety
Most toxicities were mild (grade 1 to 2) and manageable.
The overall incidence of drug-related toxicity was 36.2%
grade 1, 47.2% grade 2, and 16.6% grade 3. There were no
grade 4 toxicities. The most common grade 3 treatment-
related AEs were hypertension (20.5%), hand-foot syn-
drome (10.3%), and proteinuria (5.1%). The most frequently
observed AEs of all grade were hand-foot syndrome
(52.6%), proteinuria (52.6%), hypertension (42.1%), pain
(31.6%), neutropenia (23.7%), bilirubin increased (18.4%),transaminase increased (18.4%), fatigue (15.8%), mucositis
(15.8%), thrombocytopenia (13.2%), as presented in Table 2.
One patient experienced transient grade 3 neutropenia,
with no febrile neutropenia. Of the three possibly drug-
related SAEs recorded in the study, 2 (3.4%) deaths oc-
curred within 28 days of last treatment and the other one
was grade 2 diarrhea needing hospitalization. One death
was considered to be the result of disease progression. The
other patient died of intestinal obstruction after receiving
16 days of treatment of apatinib, which was also considered
to be because of disease progression. One patient withdrew
consent because of intolerable toxicity of grade 2 dyspnea
and grade 2 pain.
Discussion
Apatinib has demonstrated encouraging antitumor activity
across a broad range of malignancies, including gastric,
colorectal, and breast cancer, and good tolerability in
phase I study conducted in our hospital [18]. In a random-
ized, placebo-controlled phase II trial, which was also held
in our hospital, the single-agent of apatinib showed poten-
tial efficacy in heavily pretreated metastatic gastric cancer
[19]. This phase II study was held to evaluate efficacy and
safety of apatinib in patients with non-triple-negative MBC.
Previous data suggested that the potential benefit from
novel targeted agents was mediated through disease
stabilization processes rather than tumor shrinkage.
For instance, sorafenib has been reported to provide a
statistically significant PFS and OS benefit in patients
with hepatocellular and renal carcinomas without sig-
nificant response rate improvement in two large ran-
domized phase III trials [21,22]. Therefore, the primary
end point of this study was designated as PFS. ORR and
OS was the secondary endpoint. The median PFS of all 38
patients was 4.0 months (95% CI, 2.8 m – 5.2 m) and OS
was 10.3 months (95% CI, 9.1 m – 11.6 m), which were
similar to the results from another phase II study of apati-
nib in metastatic triple negative breast cancer (median
PFS was 3.3 and OS was 10.6 months) [20]. Of 36 patients
eligible for efficacy analysis, ORR was 16.7% (6/36) and
DCR was 66.7% (24/36). The surprise is 2 of the 6 CR/PR
patients were HER2-positive and 1 of them was trastuzumab-
pretreated. The results were encouraging for the efficacy
seems superior to or at least comparable with that was
reported in previous studies involved single-agent angiogen-
esis inhibitors. In a phase I/II trial of bevacizumab reported
by Cobleigh et al., 75 heavily pretreated MBC patients were
enrolled. The response rate was 9.3% and confirmed response
rate was 7%. The median duration of confirmed response was
5.5 months (range, 2.3 to 13.7 months) [23]. Two phase II
studies investigating sorafenib in pretreated MBC got a TTP
or PFS of 58 days (95% CI, 52 to 112 days) and 2.0 months
(95% CI, 1.7 to 4.1 months), respectively. The response rate
were 2% and 0, respectively [15,16]. Similarly, in a phase II
Figure 2 Kaplan-Meier curve of progression free survival (PFS).
Figure 3 Kaplan-Meier curve of overall survival (OS).
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Table 2 Adverse Events graded based on CTCAE 4.0
Adverse event Grade 1* (n, %) Grade 2 (n, %) Grade 3 (n, %) Total
Hand-foot syndrome 4(10.5) 12(31.6) 4(10.5) 20(52.6)
Proteinuria 5(13.2) 13(34.2) 2(5.3) 20(52.6)
Hypertension 1(2.6) 7(18.4) 8(21.1) 16(42.1)
Pain 7(18.4) 4(10.5) 1(2.6) 12(31.6)
Neutropenia 4(10.5) 4(10.5) 1(2.6) 9(23.7)
Bilirubin increased 2(5.3) 5(13.2) - 7(18.4)
Transaminase increased 5(13.2) 1(2.6) 1(2.6) 7(18.4)
Fatigue 3(7.9) 2(5.3) 1(2.6) 6(15.8)
Mucositis - 5(13.2) 1(2.6) 6(15.8)
Thrombocytopenia 4(10.5) 1(2.6) - 5(13.2)
Hematuria 4(10.5) - - 4(10.5)
Anorexia - 2(5.3) 1(2.6) 3(7.9)
Dizziness 2(5.3) 1(2.6) - 3(7.9)
Fever 2(5.3) - - 2(5.3)
Diarrhea 1(2.6) 1(2.6) - 2(5.3)
Skin ulceration - 1(2.6) 1(2.6) 2(5.3)
Vomiting 1(2.6) - - 1(2.6)
Ventricular arrhythmia 1(2.6) - - 1(2.6)
Dyspnea - 1(2.6) - 1(2.6)
*According to CTCAE 4.0.
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ORR was 11% and the median TTP was 10 weeks [17]. The
median overall survival in these trials were 43 weeks for beva-
cizumab [23], 37 weeks for sorafenib [15] and 38 weeks for
sunitinib [17]. It was therefore concluded that single-agent
activity of angiogenesis inhibitors was limited and combin-
ation with standard chemotherapy was recommended. As a
result, a series of four randomized, double-blind, placebo-
controlled Phase IIb Trials were developed to Investigate the
Efficacy of Sorafenib (TIES) when added to selected chemo-
therapies for HER2-negative MBC. In the SOLTI-0701 study,
sorafenib plus capecitabine as first- or second-line signifi-
cantly improved median PFS compared with placebo plus
capecitabine (6.4 vs 4.1 months, HR = 0.58, 95% CI, 0.41–
0.81, P = 0.001) [24]. The AC01B07 study reported that
the combination of sorafenib with gemcitabine or capecit-
abine in patients progressed during or after bevacizumab
got a median PFS of 3.4 months and an ORR of 19.8%
[25]. Oppositely, sorafenib plus first-line paclitaxel did not
significantly improve PFS (6.9 months for sorafenib vs
5.6 months for placebo, HR = 0.788, 95% CI, 0.558-1.112,
P = 0.1715, 1-sided P = 0.0857) in the NU07B1 study [26],
nor did its combination with docetaxel and/or letrozole as
first-line treatment in the FM-B07-01 study [27]. Besides
the older VEGF-TKIs of sorafenib and sunitinib, the more
recently introduced VEGF-TKI of axitinib, which was able
to inhibit VEGF receptors at subnanomolar concentrations,
also didn’t improve TTP when combined with docetaxel infirst-line MBC treatment compared with docetaxel plus
placebo (8.1 v 7.1 months, HR = 1.24, 95% CI, 0.82 -1.87,
1-sided P = 0.156). However, in the subgroup analysis of
patients who had received prior adjuvant chemotherapy,
an improvement in TTP was observed (9.2 v 7.0 months,
P = 0.043), suggesting the potential of axitinib to reverse
chemotherapy resistance [28]. Although the data from
those studies above all indicated potential activity for
VEGF-TKIs in combination with selected chemotherapies,
phase III trials were necessary for confirmation. We hy-
pothesized that VEGF-TKIs might be effective in breast
cancer with high angiogenesis dependency and the molecu-
lar subtypes of breast cancer such as TNBC or non-TNBC
was not a potential efficacy predictor. The most frequently
observed AEs of apatinib of all grade in this study were
hand-foot syndrome (52.6%), proteinuria (52.6%) and
hypertension (42.1%), which were similar to those re-
ported in the phase I study of apatinib in metastatic gas-
tric cancer [18]. Most AEs were mild to moderate (grades
1 to 2) in severity. 16.6% AEs were Grade 3 and no grade
4 toxicities were observed. Although one patient died
within 28 days of last treatment and one died of intestinal
obstruction after receiving 16 days of treatment of apati-
nib, the two deaths were both considered to be the result of
disease progression. Hemotologic toxicities including neu-
tropenia and thrombocytopenia were mild to moderate and
no dose interruption or reduction was needed during the
treatment. 73.7% patients experienced dose interruption
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cause of non-hemotologic toxicities. 12.1% patients
discontinued treatment due to an AE and the majorities
due to disease progression. The mechanism of hyperten-
sion is thought to be the inhibition of VEGFR in arterial
endothelial cells leading to decrease of the release of nitric
oxide, which acts on arterial smooth muscle cells to cause
vasodilation [29]. Hypertension could be well controlled by
using angiotensin receptor blocker (ARB, such as valsartan)
with or without calcium antagonists (such as amlodipine)
besides dose interruption or reduction. Hand-foot syndrome
and proteinuria could also recover rapidly and be well toler-
ated after dose interruption or reduction. As a result, careful
monitoring of toxicity and prompt dose interruption or
reduction from 500 mg to 375 mg or 250 mg were essential
during the treatment.
Conclusions
Single-agent of apatinib exhibited objective efficacy in heavily
pretreated, metastatic non-triple-negative breast cancer with
manageable toxicity, and it might be better to be tested in
breast cancer with high angiogenesis dependency. Future
studies are guaranteed to confirm value of apatinib or its
combination with standard chemotherapy in MBC.
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